A full-term infant developed respiratory distress immediately after birth, requiring a prolonged course of extra-corporeal membrane oxygenation, followed by high-frequency ventilation. She was unable to wean off mechanical ventilation, required tracheostomy, and ultimately lung transplantation. A novel mutation in the surfactant C protein gene was identified as the cause of her lung disease.
Case
The case patient was a full-term female born via spontaneous vaginal delivery. Prenatal labs were notable for GBS colonization, for which the mother received antibiotic prophylaxis. Rupture of membranes occurred 3½ h before delivery. Apgar scores were 8 at 1 min and 9 at 5 min. She was transferred from the well baby nursery to intensive care shortly after delivery because of respiratory distress. Oxygen therapy (via nasal canula) was started, and a sepsis evaluation was performed. Owing to worsening respiratory distress, she was transferred to a tertiary care center (Figure 1 ).
Chest radiograph obtained upon admission demonstrated bilateral diffuse granular opacities (Figure 2a ). Her respiratory status worsened requiring mechanical ventilation. Cardiac ultrasound demonstrated pulmonary hypertension, which was treated with inhaled Nitric Oxide, dopamine, and dobutamine. Extra-corporeal membrane oxygenation (ECMO) was initiated on day 5 of life and continued until day 26. She was then maintained on high-frequency jet ventilation until day 55 when pressurecontrol ventilation was initiated. Computed tomography (chest) on day 66 demonstrated a diffuse ground glass pattern, bronchiectasis, scattered cysts, and interlobular septal thickening. Methylprednisolone was started on day 68, with a moderate reduction of the infant's oxygen requirement and ventilatory support. Because of the persistent severe lung disease (Figure 2 ), evaluation for surfactant dysfunction mutations was performed. No mutations in the genes encoding surfactant protein-B (SFTPB) or member A3 of the ATP-binding cassette family of transporters (ABCA3) were identified. Sequencing of the surfactant protein C gene (SFTPC) revealed that she was heterozygous for a novel variation resulting in substitution of arginine for leucine in codon 45 of the SP-C precursor protein (nt134 T>G, p.L45R), results confirmed by a CLIA certified diagnostic laboratory (Ambry Genetics, Aliso Viejo, CA, USA). Tracheostomy was performed at 3½ months, and Nissen fundoplication with gastrostomy tube was performed at 4 months. She was transferred to a rehabilitation facility at 7 months ( Figure 3 ). Subsequently severe respiratory deterioration associated with a viral infection resulted in transfer for lung transplantation evaluation. Bilateral lung transplantation was performed at 20 months. Pathological specimen of the explanted lungs revealed fibrosis markedly reducing the number and size of the air sacs, airspaces filled with granular material incorporating into cholesterol clefts, macrophages, mucus material, and inflammatory cells and interstitial and bronchial adventitial inflammation. She was weaned from mechanical ventilation within a month of transplant, decanulated, and discharged home at age 23 months.
Discussion
Inherited surfactant protein abnormalities have been increasingly recognized as a cause of neonatal respiratory distress. Surfactant Protein-B (SP-B) deficiency was described in 1993 (Surfactant Metabolism Dysfunction, Pulmonary, 1, OMIM no. 265120). 1 The clinical phenotype is severe pulmonary disease in a term or near-term neonate, typically requiring aggressive ventilatory management, with death occurring within months of birth. Lung transplantation is currently the only therapeutic option. [2] [3] [4] Surfactant Protein-C gene mutations were described in 2001 (Surfactant Metabolism Dysfunction, Pulmonary, 2, OMIM no. 610913). 5 Unlike the relatively uniform severe neonatal phenotype of SP-B deficiency, the presentation of SFTPC mutations are highly variable, with the majority of subjects presenting later in life with a clinical picture of interstitial lung disease. The subject of this report had severe neonatal lung disease necessitating rescue treatment with ECMO, the use of which has not been previously reported. As was found in the case patient, a mutation on only one SFTPC allele may result in disease, which can be sporadic due to de novo mutations or inherited as an autosomal dominant trait. The vast majority of SFTPC mutations reported to date have been in the carboxy-terminal region of the SP-C precursor protein, proSP-C, and are thought to result in misfolded proSP-C. Although the precise mechanism for lung disease is not clear, the production and accumulation of abnormally folded proSP-C results in injury to type 2 pneumocytes. [2] [3] [4] ProSP-C is an integral membrane protein with the region that corresponds to the mature SP-C molecule that is secreted into the airspaces also serving to anchor it in the membrane. The mutation in the case patient is located in the region corresponding to mature SP-C, and introduces a positively charged amino acid in an extremely hydrophobic region. This mutation is thus likely to both hinder proSP-C folding and or processing, and the ability of secreted SP-C to interact with surfactant lipids. The location and nature of this mutation may partly explain the severe phenotype of our patient. As the parents were not tested for SP-C gene mutations, we were unable to determine if the mutation was inherited or arose de novo.
The third disorder related to abnormal surfactant metabolism is ABCA3 deficiency (Surfactant Metabolism Dysfunction, Pulmonary 3, OMIM no. 610921).
6 ABCA3 encodes an ATP-binding cassette transporter localized to the lamellar bodies of type 2 pneumocytes. ABCA3 deficiency results in abnormally formed lamellar bodies within type 2 pneumocytes, abnormal surfactant phospholipid composition, and impaired processing of Surfactant Protein B and C precursors. The clinical phenotype may resemble SP-B deficiency, but the severity of lung disease is variable and may present as interstitial lung disease. [2] [3] [4] This case highlights an unusual presentation of a patient with an SFTPC mutation, resembling that of SP-B or severe ABCA3 Neonatal respiratory failure BS Poterjoy et al deficiency, which has only been reported once previously. 7 The current report illustrates the need for neonatologists and pediatricians to be aware of uncommon presentations due to SFTPC mutations. Genetic surfactant dysfunction disorders should be included in the differential diagnosis for infants >36 weeks gestation (at delivery) with severe, persistent pulmonary disease of uncertain etiology, and genetic testing may establish the diagnosis non-invasively without the need for open-lung biopsy. An algorithm for the approach to the evaluation of an infant with suspected surfactant deficiency has been proposed by Cole et al.
